Display options
Cite
Zappavigna S, Abate M, Cossu AM, et al. Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. J Oncol. 2019;2019:9293560doi: 10.1155/2019/9293560.
Zappavigna, S., Abate, M., Cossu, A. M., Lusa, S., Campani, V., Scotti, L., Luce, A., Yousif, A. M., Merlino, F., Grieco, P., De Rosa, G., & Caraglia, M. (2019). Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. Journal of oncology, 20199293560. https://doi.org/10.1155/2019/9293560
Zappavigna, Silvia, et al. "Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells." Journal of oncology vol. 2019 (2019): 9293560. doi: https://doi.org/10.1155/2019/9293560
Zappavigna S, Abate M, Cossu AM, Lusa S, Campani V, Scotti L, Luce A, Yousif AM, Merlino F, Grieco P, De Rosa G, Caraglia M. Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. J Oncol. 2019 Dec 17;2019:9293560. doi: 10.1155/2019/9293560. eCollection 2019. PMID: 31929800; PMCID: PMC6942863.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2019 Dec 17;2019:9293560. doi: 10.1155/2019/9293560. eCollection 2019.

Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells.

Journal of oncology

Silvia Zappavigna, Marianna Abate, Alessia Maria Cossu, Sara Lusa, Virginia Campani, Lorena Scotti, Amalia Luce, Ali Munaim Yousif, Francesco Merlino, Paolo Grieco, Giuseppe De Rosa, Michele Caraglia

Affiliations

  1. Department of Precision Medicine, University of Campania "L. Vanvitelli", Via L. de Crecchio, 7, 80138 Naples, Italy.
  2. Biogem Scarl, Institute of Genetic Research, Laboratory of Molecular and Precision Oncology, 83031 Ariano Irpino, Italy.
  3. Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, 80131 Naples, Italy.

PMID: 31929800 PMCID: PMC6942863 DOI: 10.1155/2019/9293560

Abstract

Urotensin-II (UT-II) and its receptor (UTR) are involved in the occurrence of different epithelial cancers. In particular, UTR was found overexpressed on colon, bladder, and prostate cancer cells. The conjugation of ligands, able to specifically bind receptors that are overexpressed on cancer cells, to liposome surface represents an efficient active targeting strategy to enhance selectivity and efficiency of drug delivery systems. The aim of this study was to develop liposomes conjugated with UT-II (LipoUT) for efficient targeting of cancer cells that overexpress UTR. The liposomes had a mean diameter between 150 nm and 160 nm with a narrow size distribution (PI ≤ 0.1) and a doxo encapsulation efficiency of 96%. Moreover, the conjugation of UT-II to liposomes weakly reduced the zeta potential. We evaluated UTR expression on prostate (DU145, PC3, and LNCaP) and colon (WIDR and LoVo) cancer cells by FACS and western blotting analysis. UTR protein was expressed in all the tested cell lines; the level of expression was higher in WIDR, PC3, and LNCaP cells compared with LoVo and DU145. MTT cell viability assay showed that LipoUT-doxo was more active than Lipo-doxo on the growth inhibition of cells that overexpressed UTR (PC3, LNCaP, and WIDR) while in LoVo and DU145 cell lines, the activity was similar to or lower than that one of Lipo-doxo, respectively. Moreover, we found that cell uptake of Bodipy-labeled liposomes in PC3 and DU145 was higher for LipoUT than the not-armed counterparts but at higher extent in UTR overexpressing PC3 cells (about 2-fold higher), as evaluated by both confocal and FACS. In conclusion, the encapsulation of doxo in UT-II-targeted liposomes potentiated its delivery in UTR-overexpressing cells and could represent a new tool for the targeting of prostate and colon cancer.

Copyright © 2019 Silvia Zappavigna et al.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. Ann Endocrinol (Paris). 2019 Jun;80(3):149-152 - PubMed
  2. Oncotarget. 2016 Apr 12;7(15):20753-72 - PubMed
  3. Cell Mol Biol Lett. 2002;7(2):217-9 - PubMed
  4. J Control Release. 2001 Jul 6;74(1-3):95-113 - PubMed
  5. Circ Res. 2005 Sep 30;97(7):707-15 - PubMed
  6. Oncotarget. 2015 Oct 13;6(31):31461-78 - PubMed
  7. Vasc Health Risk Manag. 2010 Sep 07;6:723-34 - PubMed
  8. Peptides. 2001 Jul;22(7):1175-9 - PubMed
  9. ACS Nano. 2009 Jan 27;3(1):16-20 - PubMed
  10. Eur J Clin Invest. 2014;44(3):285-94 - PubMed
  11. Curr Drug Metab. 2012 Jan;13(1):4-21 - PubMed
  12. J Chemother. 2004 Nov;16 Suppl 4:94-7 - PubMed
  13. AAPS PharmSciTech. 2016 Dec;17(6):1298-1311 - PubMed
  14. J Control Release. 2011 Feb 28;150(1):2-22 - PubMed
  15. Endocr Relat Cancer. 2014 Jan 21;21(1):R67-83 - PubMed
  16. Mol Neurobiol. 2017 Sep;54(7):4879-4895 - PubMed
  17. J Med Chem. 2008 Nov 13;51(21):6639-41 - PubMed
  18. Clin Pharmacokinet. 2003;42(5):419-36 - PubMed
  19. ChemMedChem. 2016 Aug 19;11(16):1856-64 - PubMed
  20. Curr Cancer Drug Targets. 2012 Mar;12(3):186-96 - PubMed
  21. J Med Chem. 2019 Feb 14;62(3):1455-1467 - PubMed
  22. Br J Pharmacol. 2006 Jan;147(1):92-100 - PubMed
  23. J Exp Clin Cancer Res. 2014 Jun 03;33:48 - PubMed
  24. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):373-80 - PubMed
  25. Drugs. 1997;54 Suppl 4:15-21 - PubMed
  26. J Biol Chem. 1982 Jan 10;257(1):286-8 - PubMed
  27. Int J Pharm. 2007 Feb 1;329(1-2):94-102 - PubMed
  28. J Cell Biochem. 2011 Jan;112(1):341-53 - PubMed
  29. Talanta. 2006 Jan 15;68(3):693-9 - PubMed
  30. J Med Chem. 2014 Jul 24;57(14):5965-74 - PubMed
  31. Curr Med Chem. 2004 Apr;11(8):969-79 - PubMed
  32. J Med Chem. 2016 May 26;59(10):4740-52 - PubMed
  33. Curr Cancer Drug Targets. 2017;17(2):109-121 - PubMed
  34. Biosci Rep. 1998 Apr;18(2):69-78 - PubMed
  35. J Pept Sci. 2015 May;21(5):392-9 - PubMed
  36. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 - PubMed
  37. Int J Nanomedicine. 2012;7:4391-408 - PubMed
  38. Endocr Relat Cancer. 2017 Jan;24(1):R1-R12 - PubMed
  39. Expert Opin Drug Deliv. 2008 Jan;5(1):25-44 - PubMed
  40. Biomed Res Int. 2014;2014:765426 - PubMed
  41. Plant Physiol. 1980 Feb;65(2):245-8 - PubMed
  42. Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92 - PubMed
  43. Prev Med. 2003 Dec;37(6 Pt 1):627-34 - PubMed
  44. Trends Cardiovasc Med. 2000 Aug;10(6):229-37 - PubMed
  45. Curr Drug Metab. 2012 Jan;13(1):61-9 - PubMed
  46. J Amino Acids. 2013;2013:979016 - PubMed
  47. Adv Enzyme Regul. 2001;41:189-207 - PubMed
  48. Drug Deliv. 2016 May;23(4):1171-83 - PubMed
  49. Endocrine. 2017 Aug;57(2):214-219 - PubMed
  50. Biochim Biophys Acta. 2006 Oct;1758(10):1633-40 - PubMed
  51. J Vasc Res. 2013;50(2):109-23 - PubMed

Publication Types